Vicore Pharma Holding AB (STU:6Y4) Dividends per Share : €0.00 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Dividends per Share?

Vicore Pharma Holding AB's dividends per share for the three months ended in Dec. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Vicore Pharma Holding AB's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Vicore Pharma Holding AB Dividends per Share Historical Data

The historical data trend for Vicore Pharma Holding AB's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Dividends per Share Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Vicore Pharma Holding AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Vicore Pharma Holding AB's Dividends per Share

For the Biotechnology subindustry, Vicore Pharma Holding AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Dividend Yield % falls into.

Vicore Pharma Holding AB Dividends per Share Calculation

Dividends paid to per common share.

Vicore Pharma Holding AB (STU:6Y4) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Vicore Pharma Holding AB's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.035
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Vicore Pharma Holding AB Dividends per Share Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

VICO:Sweden 6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines